Cells of the zona fasciculata and zona reticularis lack aldosterone synthase (CYP11B2) that converts corticosterone to aldosterone, and thus these tissues produce only the weak mineralocorticoid corticosterone. However, both these zones do contain the CYP17A1 missing in zona glomerulosa and thus produce the major glucocorticoid, cortisol. Zona fasciculata and zona reticularis cells also contain CYP17A1, whose 17,20-lyase activity is responsible for producing the androgens, dehydroepiandosterone (DHEA) and androstenedione. Thus, fasciculata and reticularis cells can make corticosteroids and the adrenal androgens, but not aldosterone.
HCG is a highly beneficial hormone in fertility stimulation and in the treatment of low testosterone. In fact, it is rapidly becoming an integral part of many low testosterone treatment plans. For the anabolic steroid user, the performance enhancing athlete, HCG can be beneficial but it can also be damaging. Many get very carried away with on cycle use and lead themselves to an early low testosterone condition. Granted, most men will benefit from testosterone therapy at some point in their life regardless, but many steroid users end up requiring sooner and often due to improper HCG use. The hormone can be beneficial but use must be kept moderate and monitored.
In a double-blind, placebo-controlled study, 132 boys 10 to 17 years of age (mean age yrs) with heterozygous familial hypercholesterolemia (heFH) were randomized to Lovastatin (n=67) or placebo (n=65) for 48 weeks. Inclusion in the study required a baseline LDL-C level between 189 and 500 mg/dL and at least one parent with an LDL-C level >189 mg/dL. The mean baseline LDL-C value was mg/dL (range: 171 to 379 mg/dL) in the Lovastatin group compared to mg/dL (range: to mg/dL) in the placebo group. The dosage of Lovastatin (once daily in the evening) was 10 mg for the first 8 weeks, 20 mg for the second 8 weeks, and 40 mg thereafter.